Gastro Hep Advances (Jan 2023)

Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study

  • Hiroshi Nakase,
  • Yuki Hayashi,
  • Yoshihiro Yokoyama,
  • Takayuki Matsumoto,
  • Minoru Matsuura,
  • Hideki Iijima,
  • Katsuyoshi Matsuoka,
  • Naoki Ohmiya,
  • Shunji Ishihara,
  • Fumihito Hirai,
  • Daiki Abukawa,
  • Tadakazu Hisamatsu,
  • Makoto Sasaki,
  • Masahiro Iizuka,
  • Mikihiro Fujiya,
  • Takayuki Matsumoto,
  • Fukunori Kinjo,
  • Shiro Nakamura,
  • Noriko Kamata,
  • Hideki Iijima,
  • Yuri Etani,
  • Fumiaki Ueno,
  • Sakiko Hiraoka,
  • Takeo Kondo,
  • Takashi Kagaya,
  • Makoto Naganuma,
  • Kiyonori Kobayashi,
  • Taku Kobayashi,
  • Shuji Yamamoto,
  • Yuji Naito,
  • Tadakazu Hisamatsu,
  • Yoki Furuta,
  • Keichi Mitsuyama,
  • Yu Hashimoto,
  • Katsuhiro Arai,
  • Shingo Kato,
  • Itaru Iwama,
  • Motohiro Esaki,
  • Hiroki Tanaka,
  • Hiroshi Nakase,
  • Satoshi Motoya,
  • Atsuo Maemoto,
  • Toshifumi Ashida,
  • Nobuaki Nishimata,
  • Shigeaki Aono,
  • Akira Andoh,
  • Hironori Yamamoto,
  • Shunji Ishihara,
  • Toshiaki Shimizu,
  • Maeda Yasuharu,
  • Kenji Kinoshita,
  • Katuyuki Fukuda,
  • Jun Kato,
  • Ken Takeuchi,
  • Masakazu Nagahori,
  • Masakatsu Fukuzawa,
  • Masayuki Saruta,
  • Takayoshi Suzuki,
  • Michio Itabashi,
  • Masaru Shinozaki,
  • Soichiro Ishihara,
  • Naoki Yoshimura,
  • Katsuyoshi Matsuoka,
  • Yoichi Kakuta,
  • Kenichi Takahashi,
  • Keiichi Tominaga,
  • Ryosuke Sakemi,
  • Sohachi Nanjo,
  • Shusaku Yoshikawa,
  • Keiji Ozeki,
  • Ayako Fuchigami,
  • Takehiko Katsurada,
  • Kenji Watanabe,
  • Hirotake Sakuraba,
  • Fumihito Hirai,
  • Takashi Hisabe,
  • Shigeru Iwase,
  • Naoki Ohmiya,
  • Ryota Hokari,
  • Katsuhiko Nakai,
  • Takeshi Ueda,
  • Daiki Abukawa,
  • Shojiro Yamamoto,
  • Kazutaka Koganei,
  • Reiko Kunisaki,
  • Akira Hokama

Journal volume & issue
Vol. 2, no. 8
pp. 1056 – 1065

Abstract

Read online

Background and Aims: Japan has experienced 8 waves of the coronavirus disease 2019 (COVID-19) outbreak over the past 3 years, resulting in an increasing number of deaths and incidence of severe infections. This study aimed to analyze the data from the Japanese inflammatory bowel disease (IBD) patients with COVID-19 registry (J-COSMOS) up to the eighth wave to investigate the clinical course of IBD patients with COVID-19 and factors contributing to disease severity. Methods: In this multicenter, observational, cohort study, we analyzed a cohort of 1308 IBD patients diagnosed with COVID-19, enrolled across 77 participating facilities in the J-COSMOS registry from June 2020 to December 2022. Data on age, sex, IBD (classification, treatment, and activity), and COVID-19 (symptoms, severity, and treatment) were analyzed. Results: The majority of patients (76%) were in clinical remission. According to the World Health Organization classification of COVID-19 severity, 98.4% of IBD patients had nonsevere disease, while 1.6% of patients had severe or critical disease. COVID-19 did not affect disease activity in most IBD patients. Stepwise logistic regression analysis revealed that high body mass index, and cerebrovascular disease were risk factors for severe COVID-19. Corticosteroids could affect COVID-19 severity, whereas anti-tumor necrosis factor α antibodies and thiopurines were associated with a reduced risk of severe COVID-19. No deaths were observed among IBD patients with COVID-19 registered in this cohort. Conclusion: The impact of COVID-19 on IBD disease activity and factors associated with COVID-19 severity were consistent with findings of previous reports. No deaths in Japanese patients with IBD were observed.

Keywords